{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:59:16Z","timestamp":1791849556858,"version":"4.3.4"},"reference-count":34,"publisher":"Galenos Yayinevi","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["dir"],"published-print":{"date-parts":[[2023,9,1]]},"DOI":"10.4274\/dir.2023.232186","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T11:57:10Z","timestamp":1688385430000},"page":"647-655","source":"Crossref","is-referenced-by-count":4,"title":["Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, &lt;sup&gt;(68)&lt;\/sup&gt;Ga-PSMA PET\/CT, PSA, and PSA-density comparison study"],"prefix":"10.4274","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5821-670X","authenticated-orcid":false,"given":"Hu\u0308seyin","family":"Akkaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2144-2460","authenticated-orcid":false,"given":"Okan","family":"Dilek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0989-9732","authenticated-orcid":false,"given":"Selim","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5504-4487","authenticated-orcid":false,"given":"Zeynel Abidin","family":"Ta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3946-6222","authenticated-orcid":false,"given":"\u0130hsan Sabri","family":"\u00d6ztu\u0308rk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1510-6257","authenticated-orcid":false,"given":"Bozkurt","family":"Gu\u0308lek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol. 2019;76(3):340-351. [CrossRef]","DOI":"10.1016\/j.eururo.2019.02.033"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Sauter G, Steurer S, Clauditz TS, et al. Clinical utility of quantitative Gleason grading in prostate biopsies and prostatectomy specimens. Eur Urol. 2016;69(4):592-598. [CrossRef]","DOI":"10.1016\/j.eururo.2015.10.029"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Boesen L, N\u00f8rgaard N, L\u00f8gager V, et al. Prebiopsy biparametric magnetic resonance imaging combined with prostate-specific antigen density in detecting and ruling out Gleason 7-10 prostate cancer in biopsy-na\u00efve men. Eur Urol Oncol. 2019;2(3):311-319. [CrossRef]","DOI":"10.1016\/j.euo.2018.09.001"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Godtman RA, Kollberg KS, Pihl CG, M\u00e5nsson M, Hugosson J. The association between age, prostate cancer risk, and higher Gleason score in a long-term screening program: results from the G\u00f6teborg-1 Prostate Cancer Screening Trial. Eur Urol. 2022;82(3):311-317. [CrossRef]","DOI":"10.1016\/j.eururo.2022.01.018"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Tan CH, Hobbs BP, Wei W, Kundra V. Dynamic contrast-enhanced MRI for the detection of prostate cancer: meta-analysis. AJR Am J Roentgenol. 2015;204(4):W439-W448. [CrossRef]","DOI":"10.2214\/AJR.14.13373"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Winkel DJ, Heye TJ, Benz MR, et al. Compressed sensing radial sampling MRI of prostate perfusion: utility for detection of prostate cancer. Radiology. 2019;290(3):702-708.\u00a0[CrossRef]","DOI":"10.1148\/radiol.2018180556"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10(3):223-232. [CrossRef]","DOI":"10.1002\/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Zhao J, Mangarova DB, Brangsch J, et al. Correlation between intraprostatic PSMA Uptake and MRI PI-RADS of [68Ga]Ga-PSMA-11 PET\/MRI in patients with prostate cancer: comparison of PI-RADS version 2.0 and PI-RADS version 2.1. Cancers (Basel). 2020;12(12):3523. [CrossRef]","DOI":"10.3390\/cancers12123523"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Singanamalli A, Rusu M, Sparks RE, et al. Identifying in vivo DCE MRI markers associated with microvessel architecture and gleason grades of prostate cancer. J Magn Reson Imaging. 2016;43(1):149-158.\u00a0[CrossRef]","DOI":"10.1002\/jmri.24975"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Michallek F, Huisman H, Hamm B, Elezkurtaj S, Maxeiner A, Dewey M. Prediction of prostate cancer grade using fractal analysis of perfusion MRI: retrospective proof-of-principle study. Eur Radiol. 2022;32(5):3236-3247. [CrossRef]","DOI":"10.1007\/s00330-021-08394-8"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Zhao J, Hamm B, Brenner W, Makowski MR. Lesion-to-background ratio threshold value of SUVmax of simultaneous [68Ga]Ga-PSMA-11 PET\/MRI imaging in patients with prostate cancer. Insights Imaging. 2020;11(1):137. [CrossRef]","DOI":"10.1186\/s13244-020-00926-y"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Demirci E, Kabasakal L, \u015eahin OE, et al. Can SUVmax values of Ga-68-PSMA PET\/CT scan predict the clinically significant prostate cancer? Nucl Med Commun. 2019;40(1):86-91. [CrossRef]","DOI":"10.1097\/MNM.0000000000000942"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Kwan TN, Spremo S, Teh AYM, McHarg D, Thangasamy I, Woo HH. Performance of Ga-68 PSMA PET\/CT for diagnosis and grading of local prostate cancer. Prostate Int. 2021;9(2):107-112. [CrossRef]","DOI":"10.1016\/j.prnil.2020.07.008"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Donato P, Morton A, Yaxley J, et al. 68Ga-PSMA PET\/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: Is 68Ga-PSMA PET\/CT guided biopsy the future? Eur J Nucl Med Mol Imaging. 2020;47(8):1843-1851. [CrossRef]","DOI":"10.1007\/s00259-019-04620-0"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Yusim I, Krenawi M, Mazor E, Novack V, Mabjeesh NJ. The use of prostate specific antigen density to predict clinically significant prostate cancer. Sci Rep. 2020;10(1):20015. [CrossRef]","DOI":"10.1038\/s41598-020-76786-9"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Aminsharifi A, Howard L, Wu Y, et al. Prostate specific antigen density as a predictor of clinically significant prostate cancer when the prostate specific antigen is in the diagnostic gray zone: defining the optimum cutoff point stratified by race and body mass index. J Urol. 2018;200(4):758-766. [CrossRef]","DOI":"10.1016\/j.juro.2018.05.016"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Egevad L, Delahunt B, Srigley JR, Samaratunga H. International Society of Urological Pathology (ISUP) grading of prostate cancer - an ISUP consensus on contemporary grading. APMIS. 2016;124(6):433-435. [CrossRef]","DOI":"10.1111\/apm.12533"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Fleiss JL, Cohen J. The equivalence of weighted kappa and the intraclass correlation coefficient as measures of reliability. Educ Psychol Meas. 1973;33(3):613-619. [CrossRef]","DOI":"10.1177\/001316447303300309"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Tulsyan S, Das CJ, Tripathi M, Seth A, Kumar R, Bal C. Comparison of 68Ga-PSMA PET\/CT and multiparametric MRI for staging of high-risk prostate cancer 68Ga-PSMA PET and MRI in prostate cancer. Nucl Med Commun. 2017;38(12):1094-1102.\u00a0[CrossRef]","DOI":"10.1097\/MNM.0000000000000749"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Jochumsen MR, S\u00f6rensen J, Tolbod LP, et al. Potential synergy between PSMA uptake and tumour blood flow for prediction of human prostate cancer aggressiveness. EJNMMI Res. 2021;11(1):12.\u00a0[CrossRef]","DOI":"10.1186\/s13550-021-00757-y"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Lennartz S, T\u00e4ger P, Zopfs D, et al. Lymph node assessment in prostate cancer: evaluation of iodine quantification with spectral detector CT in correlation to PSMA PET\/CT. Clin Nucl Med. 2021;46(4):303-309. [CrossRef]","DOI":"10.1097\/RLU.0000000000003496"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Uprimny C, Kroiss AS, Decristoforo C, et al. 68Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging. 2017;44(6):941-949. [CrossRef]","DOI":"10.1007\/s00259-017-3631-6"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Bud\u00e4us L, Leyh-Bannurah SR, Salomon G, et al. Initial experience of (68)Ga-PSMA PET\/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2016;69(3):393-396. [CrossRef]","DOI":"10.1016\/j.eururo.2015.06.010"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Barbosa FG, Queiroz MA, Nunes RF, Marin JFG, Buchpiguel CA, Cerri GG. Clinical perspectives of PSMA PET\/MRI for prostate cancer. Clinics (Sao Paulo). 2018;73(Suppl 1):e586s. [CrossRef]","DOI":"10.6061\/clinics\/2018\/e586s"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Zhao J, Kader A, Mangarova DB, et al. Dynamic contrast-enhanced mri of prostate lesions of simultaneous [68Ga]Ga-PSMA-11 PET\/MRI: comparison between intraprostatic lesions and correlation between perfusion parameters. Cancers (Basel). 2021;13(6):1404.\u00a0[CrossRef]","DOI":"10.3390\/cancers13061404"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"van Niekerk CG, van der Laak JA, Hambrock T, et al. Correlation between dynamic contrast-enhanced MRI and quantitative histopathologic microvascular parameters in organ-confined prostate cancer. Eur Radiol. 2014;24(10):2597-2605. [CrossRef]","DOI":"10.1007\/s00330-014-3301-z"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Winkel DJ, Heye TJ, Benz MR, et al. Compressed sensing radial sampling MRI of prostate perfusion: utility for detection of prostate cancer. Radiology. 2019;290(3):702-708.\u00a0[CrossRef]","DOI":"10.1148\/radiol.2018180556"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Cai W, Li F, Wang J, et al. A comparison of arterial spin labeling perfusion MRI and DCE-MRI in human prostate cancer. NMR Biomed. 2014;27(7):817-825. [CrossRef]","DOI":"10.1002\/nbm.3124"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Sung YS, Kwon HJ, Park BW, et al. Prostate cancer detection on dynamic contrast-enhanced MRI: computer-aided diagnosis versus single perfusion parameter maps. AJR Am J Roentgenol. 2011;197(5):1122-1129. [CrossRef]","DOI":"10.2214\/AJR.10.6062"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Ren J, Huan Y, Wang H, et al. Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis. Clin Radiol. 2008;63(2):153-159. [CrossRef]","DOI":"10.1016\/j.crad.2007.07.023"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Chen YJ, Chu WC, Pu YS, Chueh SC, Shun CT, Tseng WY. Washout gradient in dynamic contrast-enhanced MRI is associated with tumor aggressiveness of prostate cancer. J Magn Reson Imaging. 2012;36(4):912-919. [CrossRef]","DOI":"10.1002\/jmri.23723"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Vos EK, Litjens GJ, Kobus T, et al. Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3 T. Eur Urol. 2013;64(3):448-455. [CrossRef]","DOI":"10.1016\/j.eururo.2013.05.045"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Kim JK, Hong SS, Choi YJ, et al. Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J Magn Reson Imaging. 2005;22(5):639-646. [CrossRef]","DOI":"10.1002\/jmri.20431"},{"key":"ref33","unstructured":"Ziayee F, Mueller-Lutz A, Gross J, et al. Arterial input function for quantitative dynamic contrast-enhanced MRI to diagnose prostate cancer. Diagn Interv Radiol. 2022;28(2):108-114. [CrossRef]"}],"container-title":["Diagnostic and Interventional Radiology"],"original-title":[],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T08:18:53Z","timestamp":1738311533000},"score":1,"resource":{"primary":{"URL":"https:\/\/dirjournal.org\/articles\/doi\/dir.2023.232186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,9,1]]},"published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.4274\/dir.2023.232186","relation":{},"ISSN":["1305-3825","1305-3612"],"issn-type":[{"value":"1305-3825","type":"print"},{"value":"1305-3612","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}